Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial-Reference-Cited by-同舟云学术

Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial

Published:2023-08 Issue:8 Volume:24 Page:881-891
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Albiges Laurence,Gurney Howard,Atduev Vagif,Suarez Cristina,Climent Miguel A,Pook David,Tomczak Piotr,Barthelemy Philippe,Lee Jae Lyun,Stus Viktor,Ferguson Thomas,Wiechno Pawel,Gokmen Erhan,Lacombe Louis,Gedye Craig,Perini Rodolfo F,Sharma Manish,Peng Xiang,Lee Chung-Han

Funder

Eisai

Merck Sharp and Dohme

Publisher

Elsevier BV

Subject

Oncology

Reference23 articles.

1. Renal cell carcinoma;Hsieh;Nat Rev Dis Primers,2017

2. Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial;Tannir;Eur Urol,2016

3. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial;Armstrong;Lancet Oncol,2016

4. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Escudier;Ann Oncol,2019

5. Open-label, single-arm phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced clear cell renal cell carcinoma;McDermott;J Clin Oncol,2021

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Clinicopathological Characteristics and Prognosis of 55 Patients With TFE3-Rearranged Renal Cell Carcinomas;Clinical Genitourinary Cancer;2024-10

2. Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma;Journal of Chemotherapy;2024-09-10

3. Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de‐differentiation (ARON‐1 study);International Journal of Cancer;2024-09-07

4. Clinical outcomes of first-line combination therapy with immune checkpoint inhibitor for metastatic non-clear cell renal cell carcinoma: a multi-institutional retrospective study in Japan;International Journal of Clinical Oncology;2024-09-02

5. Clinical outcomes and prognostic factors in metastatic nonclear cell renal cell carcinoma treated with immuno-oncology combination therapy;Japanese Journal of Clinical Oncology;2024-08-23